DBPR114 is a novel small molecule multi-target kinase inhibitor. DBPR114 significantly shrank tumor growth of 8 different cancer cells in vivo by intravenous administration. These results indicate the potential of DBPR114 as a novel development candidate for various cancers, including AML, pancreatic, livergastric cancers,all important cancers currently without very effective treatments. DBPR114 was approved for IND by US FDATFDA in 2017.

DBPR114 has demonstrated broad spectrum antitumor activities against a variety of human cancer lines both in vitroin vivo. 
DBPR114 is superior to sorafenib in Hep3B (Liver cancer) xenograft study. 
DBPR114 is superior to gemcitabine in MIA PaCa-2 (Pancreatic cancer) xenograft study.

Multi-target drugs can more effectively inhibit cancer cell proliferation, overcome drug resistance,show betterbroader anti-cancer effects. DBPR114 may provide therapeutic benefit over existing treatment modalities for the tough to treat cancers such as pancreatic, livergastric cancers. DBPR114 thus has the potential to be developed as first-in-class asset for GI cancers (gastric, l